

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Stefan Gafner, et al. :Group Art Unit:1654
Serial No. 10/655,935 :Examiner:
Filed: September 5, 2003 :
For EXTRACT OF MAD-DOG SKULLCAP

**INFORMATION DISCLOSURE STATEMENT
WITHIN 3 MONTHS OF FILING OR PRIOR TO FIRST OFFICE ACTION**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

S I R:


A list of documents on form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is submitted in the above identified application in compliance with 37 CFR 1.97 & 1.98. This paper is submitted in accordance with 37 CFR 1.97(b) (within three (3) months of the application filing date or prior to a first Office Action on the merits).

2/10/04

Date

Patrick R. Scanlon

Patrick R. Scanlon
Reg. No. 34,500
207-791-1276



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/655,935
		Filing Date	September 5, 2003
		First Named Inventor	Stefan Gafner
		Art Unit	1654
		Examiner Name	
Sheet 1	of 2	Attorney Docket Number	TOM2809US02

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Napralert Profile for Scutellaria Lateriflora, 7/29/99, citing BURLAGE, HM, Coll. Pharm. Univ. Texas, Austin	
	2	MILLSPAUGH, CF, Scutellaria, American Medicinal Plants, pp. 469-472, Dover Publications, New York	
	3	YAGHMAI, MS, Volatile Constituents of Scutellaria lateriflora L., Flavour and Fragrance Journal, 1988, pp. 27-31, Vol. 3, John Wiley & Sons, Ltd.	
	4	MAURIZIO, B, et al., Neo-Clerodane Diterpenoids From Scutellaria Lateriflora, Phytochemistry, 1998, pp. 687-691, Vol. 48, No. 4, Elsevier Science Ltd., Great Britain	
	5	GAFNER, S, et al., Adulteration of Mad-Dog Skullcap (Scutellaria Lateriflora L.): An Example of the Importance of Classical Pharmacognosy, Abstracts of plenary lectures and posters, 44th Annual Meeting of the American Society of Pharmacognosy, Poster 228, 2003, p. 244, Chapel Hill, NC	
	6	LIAO, JF, et al., Benzodiazepine Binding Site - Interactive Flavones from Scutellaria baicalensis Root, Planta Medica, Vol. 64, 1998, pp. 571-572, National Research Institute of Chinese Medicine, Republic of China	
	7	KWOK, MH, et al., Interaction of Flavones from the Roots of Scutellaria baicalensis with the Benzodiazepine Site, Planta Medica, Vol. 66, 2000, pp. 91-93, Georg Thieme Verlag Stuttgart, New York	
	8	WANG, HY, et al., Structure-Activity Relationships of Flavonoids, Isolated from Scutellaria baicalensis, Binding to Benzodiazepine Site of GABA A Receptor Complex, Planta Med. 2002, Vol. 68, pp. 1059-1062, Georg Thieme Verlag Stuttgart, New York	
	9	GAFNER, S, et al., Inhibition of [3H]-LSD Binding to 5-HT ₇ Receptors by Flavonoids from Scutellaria lateriflora, Journal of Natural Products, 2003, pp. 535-537, Vol. 66., No. 4, American Chemical Society and American Society of Pharmacognosy	
	10	KIM, DH, et al., Intestinal Bacterial metabolism of flavnoids and its relation to some biological activities, Arch Pharm. Res., 1998, Vol. 21, pp. 17-23, summary accessed from Pub Med website	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known		
	Application Number		10/655,935
	Filing Date		September 5, 2003
	First Named Inventor		Stefan Gafner
	Art Unit		1654
	Examiner Name		
Sheet 2	of 2	Attorney Docket Number TOM2809US02	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	AKAO, T, et al., Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form, J Pharm Pharmacol, 2000, Vol. 52, pp. 1563-1568, summary accessed from Pub Med website	
	12	WOLFSON, PE, et al. An Investigation into the Efficacy of Scutellaria Lateriflora in Healthy Volunteers, Alternative Therapies, Mar/Apr, 2003, Vol. 9, No. 2, 74-78, InnoVision Communications, CA	
	13	LIAO, JF, et al., Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice, European Journal of Pharmacology 464, 31 January 2003, pp. 141-146, Elsevier Science	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.